Bristol-Myers Squibb has grabbed an option on an early-stage program for idiopathic pulmonary fibrosis this morning, forging a deal to potentially buy out Denmark’s Galecto Biotech for up to $444 million–if the drug pans out in the clinic.

…read more

Source: Bristol-Myers beefs up fibrosis pipeline with $444M option deal


0 No comments